证券代码：601089 证券简称：福元医药 公告编号：临 2025-050 北京福元医药股份有限公司 关于利丙双卡因乳膏获得药品注册证书的公告 （二）浅层外科手术。例如:生殖器粘膜，在浅层外科手术或浸润 麻醉之前的腿部溃疡清洁/清创术。 福元药业于2023年12月26日获得申报受理通知书，并于近日获得国 家药监局批准。根据国家相关政策规定，本次获得《药品注册证书》 视同通过一致性评价。 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承 担法律责任。 近日，北京福元医药股份有限公司（以下简称"公司"）全资子 公司福元药业有限公司（以下简称"福元药业"）收到了国家药品监 督管理局(以下简称"国家药监局") 颁发的利丙双卡因乳膏（规格： 5g:利多卡因 125mg 与丙胺卡因 125mg，以下简称"该药品"）《药 品注册证书》（证书编号：2025S02053）。现将相关情况公告如下： 药品名称 药品通用名称：利丙双卡因乳膏 英文名/拉丁名：Lidocaine and Prilocaine Cream 剂型 乳膏剂 注册分类 化学药品4类 规格 5 ...

证券代码：601089 证券简称：福元医药 公告编号：临 2025-051 北京福元医药股份有限公司 关于盐酸贝尼地平片获得药品注册证书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承 担法律责任。 近日，北京福元医药股份有限公司（以下简称"公司"）收到了 国家药品监督管理局(以下简称"国家药监局")颁发的盐酸贝尼地平 片（规格：4mg，以下简称"该药品")《药品注册证书》(证书编号： 2025S02068)，批准该药品生产。现将相关情况公告如下： 公司于 2024 年 4 月 29 日获得申报受理通知书，并于近日获得国 家药监局批准。根据国家相关政策规定，本次获得《药品注册证书》， 视同通过一致性评价。 截至本公告日，公司针对该药品累计研发投入为人民币 431.48 万元(未经审计)。 三、同类药品的市场状况 根据米内网数据显示，2024 年中国三大终端六大市场盐酸贝尼地 平片的销售额约为 10.07 亿元，其中城市公立医院和县级公立医院销 售额为 6.59 亿元，城市社区中心和乡镇卫生院销售额为 1.26 亿元， 城市实体药店和 ...

证券代码：601089 证券简称：福元医药 公告编号：临 2025-049 北京福元医药股份有限公司 关于盐酸阿莫罗芬搽剂获得药品注册证书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承 担法律责任。 近日，北京福元医药股份有限公司（以下简称"公司"）全资子 公司福元药业有限公司（以下简称"福元药业"）收到了国家药品监 督管理局(以下简称"国家药监局") 颁发的盐酸阿莫罗芬搽剂（规格： 5%（2.5ml:125mg，按 C21H35NO 计），以下简称"该药品"）《药品 注册证书》（证书编号：2025S01976）。现将相关情况公告如下： 药品名称 药品通用名称：盐酸阿莫罗芬搽剂 英文名/拉丁名：Amorolfine Hydrochloride Liniment 剂型 搽剂 注册分类 化学药品4类 规格 5%（2.5ml：125mg，按C21H35NO计） 药品批准文号 国药准字H20254685 药品注册标准编号 YBH14682025 处方药/非处方药 非处方药 申请事项 药品注册（境内生产） 一、药品注册证书主要内容 | 审批 ...

Core Viewpoint - Fuyuan Pharmaceutical (601089) has received the drug registration certificate for Amorolfine Hydrochloride Solution from the National Medical Products Administration, indicating a significant advancement in its product portfolio aimed at treating fungal infections of nails [1] Company Summary - Fuyuan Pharmaceutical's wholly-owned subsidiary, Fuyuan Pharmaceutical Co., Ltd., has been granted the drug registration certificate for Amorolfine Hydrochloride Solution, which is intended for the treatment of nail infections caused by sensitive fungi [1] - The company received the acceptance notice for the application on January 2, 2024, and has recently obtained approval [1] - As of the announcement date, Fuyuan Pharmaceutical has invested a total of RMB 3.9783 million in the research and development of this drug [1] Industry Summary - According to data from Minet, the sales revenue of Amorolfine Hydrochloride Solution in China's three major terminal markets is estimated to be approximately RMB 456 million in 2024 [1]

Core Viewpoint - Fuyuan Pharmaceutical (601089) has received the drug registration certificate for Lidocaine and Prilocaine Cream from the National Medical Products Administration, indicating a significant milestone in its product development and market entry [1] Company Summary - Fuyuan Pharmaceutical's wholly-owned subsidiary, Fuyuan Pharmaceutical Co., Ltd., has been granted the drug registration certificate for Lidocaine and Prilocaine Cream, which is intended for local anesthesia of the skin [1] - The drug registration standard number is YBH15772025, with a specification of 5g containing 125mg of Lidocaine and 125mg of Prilocaine [1] - The total R&D investment for this drug by Fuyuan Pharmaceutical Co., Ltd. has reached RMB 5.3826 million [1] Industry Summary - According to data from Minet, the estimated sales revenue for Lidocaine and Prilocaine Cream in China's three major terminal markets is approximately RMB 615 million in 2024 [1]

Group 1 - TaiLong Pharmaceutical plans to apply for the registration and issuance of super short-term financing bonds not exceeding 800 million yuan, with a maturity of no more than 270 days, for purposes including replacing bank loans and supplementing working capital [1] - GuoXin Technology won a bid for a 46 million yuan automotive airbag ignition driver chip project, indicating its growing presence in the automotive semiconductor market [1] - GuoMai Technology expects a net profit increase of 60.52% to 100.33% for the first half of 2025, with a projected net profit of 125 million to 156 million yuan [2] Group 2 - ChangAluminum's subsidiary signed a 165 million yuan contract for the customized construction of a clinical and industrial base for a vaccine project, highlighting its involvement in the biopharmaceutical sector [3] - ZhongSalt Chemical acquired exploration rights for natural soda ash in Inner Mongolia for 929,000 yuan, expanding its resource base [4] - Six Kingdom Chemical announced the resignation of its deputy general manager, which may impact its operational strategy [5][6] Group 3 - FuYuan Pharmaceutical received a drug registration certificate for Bisoprolol Amlodipine tablets, indicating its expansion in the hypertension treatment market [7][8] - GuanShi Technology's subsidiary received a government subsidy of 7 million yuan, which is 45.29% of its net profit for the previous year, enhancing its financial position [9] - XiZhong Technology plans to repurchase shares worth between 75 million and 150 million yuan, aimed at employee stock ownership plans or equity incentives [10] Group 4 - BeiLu Pharmaceutical's subsidiary received approval for the raw material drug Iopromide, which is used as a contrast agent for various imaging examinations [12] - HongHui New Materials obtained a patent for a water-based protective paint for hardware parts, enhancing its product portfolio [13] - BoJi Pharmaceutical's subsidiary received two patents related to high bioavailability formulations, indicating innovation in biopharmaceutical technology [14] Group 5 - ChengJian Development received a cash dividend of 23.625 million yuan from its investment in Huaneng Capital, contributing to its investment income [15] - JiuZhou Pharmaceutical's subsidiary received a drug registration certificate for Sildenafil Citrate orally disintegrating tablets, expanding its product offerings in the erectile dysfunction treatment market [16] - RuiAng Gene's subsidiary received a government subsidy of 176,290 yuan, supporting its operational activities [17] Group 6 - FengFan Technology plans to acquire 100% equity of a subsidiary for 48 million yuan, indicating strategic expansion in the renewable energy sector [18] - AoJing Medical's subsidiary received a medical device production license, allowing it to manufacture absorbable surgical dressings [19] - TaiLin Bio's subsidiary won land use rights for an industrial site, facilitating its high-performance filter project [20] Group 7 - KaiPu Bio received a patent for a method and device for analyzing genomic copy number variations, enhancing its capabilities in molecular diagnostics [21] - Shanghai KaiBao received a drug registration certificate for Phlegm-Heat Clearing Capsules, which can be used in the treatment of COVID-19 symptoms [23] - TuoJing Life received two patents for high uniformity streptavidin applications, improving its diagnostic product stability [25] Group 8 - AnKe Bio's AK2024 injection received approval for clinical trials, marking a significant advancement in cancer treatment [26] - HuanYuan Pharmaceutical expects a net profit of 142 million to 160 million yuan for the first half of 2025, reflecting substantial growth [27] - JinHongShun terminated a major asset restructuring plan due to a lack of consensus among parties involved, impacting its strategic direction [28] Group 9 - HeZhan Energy signed a 177 million yuan contract for the sale of steel-concrete tower structures, indicating strong demand in the renewable energy sector [29] - InSai Group's acquisition plan for an 80% stake in ZhiZheTongXing was accepted by the Shenzhen Stock Exchange, indicating growth in its consulting business [30] - JiuDian Pharmaceutical received a drug registration certificate for Zinc Granules, enhancing its product line in gastrointestinal treatments [32] Group 10 - GuoYao Modern plans to publicly transfer a 51% stake in its subsidiary to optimize resource allocation [34] - GuoYao Modern's subsidiary received a drug registration certificate for Perindopril Indapamide tablets, expanding its hypertension treatment portfolio [36] - ZhongGong International signed a 175 million yuan engineering consulting service contract, showcasing its capabilities in project management [38] Group 11 - China Railway won contracts worth approximately 5.343 billion yuan for overseas construction projects, indicating its strong international presence [39] - JunPu Intelligent signed a framework contract for humanoid robot sales worth about 28.25 million yuan, reflecting growth in the robotics sector [41] - Sinopec's chairman resigned due to age, which may lead to changes in corporate governance [42] Group 12 - JiuFeng Energy's controlling shareholder plans to reduce their stake by up to 0.71%, indicating potential changes in ownership structure [44] - Zhejiang Oriental's subsidiary plans to establish a 1.74 billion yuan equity investment fund, focusing on strategic emerging industries [46] - ChenGuang New Materials received a government subsidy of 26 million yuan, significantly impacting its financial performance [48]

证券代码：601089 证券简称：福元医药 公告编号：临 2025-048 北京福元医药股份有限公司 由协和发酵麒麟研制的盐酸贝尼地平片，最早于 1991 年 10 月获 日本批准上市，2004 年 3 月，经国家药品监督管理局批准，盐酸贝尼 地平片在国内获批上市，用于原发性高血压，心绞痛。 关于盐酸贝尼地平片获得药品注册证书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承 担法律责任。 近日，北京福元医药股份有限公司（以下简称"公司"）收到了 国家药品监督管理局(以下简称"国家药监局")颁发的盐酸贝尼地平 片（规格：8mg）(以下简称"该药品")《药品注册证书》(证书编号： 2025S01906)，批准该药品生产。现将相关情况公告如下： 药品名称 药品通用名称：盐酸贝尼地平片 英文名/拉丁名：Benidipine Hydrochloride Tablets 剂型 片剂 注册分类 化学药品4类 规格 8mg 药品批准文号 国药准字H20254631 药品注册标准编号 YBH13712025 申请事项 药品注册（境内生产） 审批结论 ...

| 一、药品注册证书主要内容 | | --- | | | 批准注册，发给药品注册证书。质量标准、说 明书、标签及生产工艺照所附执行。药品生产 | | --- | --- | | | 企业应当符合药品生产质量管理规范要求方可 | | | 生产销售。 | | 上市许可持有人 | 北京福元医药股份有限公司 | | 生产企业 | 北京福元医药股份有限公司 | 二、药品相关信息 由默克研制的比索洛尔氨氯地平片，最早于 2010 年 10 月通过互 认程序获批上市，参照成员国为匈牙利，2021 年 5 月，经国家药品监 督管理局批准，比索洛尔氨氯地平片在国内获批上市。本品作为高血 压治疗的替代疗法，用于目前同时服用与复方制剂剂量相同的单药且 血压控制良好的患者。 公司于 2024 年 2 月 26 日获得申报受理通知书，并于近日获得国 家药监局批准。根据国家相关政策规定，本次获得《药品注册证书》， 视同通过一致性评价。 证券代码：601089 证券简称：福元医药 公告编号：临 2025-047 北京福元医药股份有限公司 关于比索洛尔氨氯地平片获得药品注册证书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、 ...

Core Viewpoint - The company has received the drug registration certificate for Benidipine Hydrochloride Tablets (8mg) from the National Medical Products Administration, which will enhance its product line and market competitiveness [1] Group 1: Drug Approval and Market Impact - The drug was first approved in Japan in 1991 and received domestic approval in 2004 for the treatment of primary hypertension and angina [1] - The company received the acceptance notice for the application on March 5, 2024, and has recently been granted approval [1] - The estimated sales revenue for Benidipine Hydrochloride Tablets in China's three major terminal markets is approximately 1.007 billion yuan in 2024 [1] Group 2: R&D Investment - The total research and development investment for this drug by the company amounts to 5.2737 million yuan [1]

Investment Rating - The report maintains a "Recommended" investment rating for the healthcare sector [7]. Core Insights - The healthcare sector has shown a mixed performance, with the Shenyin Wanguo Pharmaceutical Bio Index rising by 1.60% from June 23 to June 27, 2025, underperforming the CSI 300 Index by 0.35 percentage points [2][12]. - Year-to-date, the pharmaceutical sector has increased by 6.24%, outperforming the CSI 300 Index by 6.57 percentage points, ranking 11th among 31 sectors [2][14]. - As of June 27, 2025, the valuation of the pharmaceutical sector stands at 27.54 times (TTM overall method, excluding negative values), with a premium of 140.94% compared to the CSI 300 [2][17]. Summary by Sections 1. Market Performance - The pharmaceutical sector's performance from June 23 to June 27, 2025, was a 1.60% increase, ranking 23rd among 31 sectors [12]. - The year-to-date performance shows a 6.24% increase, ranking 11th among 31 sectors [14]. 2. Important Events - The National Healthcare Security Administration released the "2025 Basic Medical Insurance Directory and Commercial Insurance Innovative Drug Directory Adjustment Application Guidelines," marking a significant step for commercial health insurance in the multi-level medical security system [4][21]. 3. Industry Perspective - The inclusion of the commercial insurance innovative drug directory indicates an enhanced role for commercial insurance in the multi-level medical security system, providing greater opportunities for the industry [5][22]. - The report expresses optimism for innovative drugs, overseas expansion, and the clearing of procurement in specific segments, suggesting a focus on companies involved in these areas [22].